Have a personal or library account? Click to login
Semaphorin 5A as a Novel Diagnostic Biomarker of Juvenile Idiopathic Arthritis Cover

Semaphorin 5A as a Novel Diagnostic Biomarker of Juvenile Idiopathic Arthritis

Open Access
|May 2025

References

  1. Cheng Q, Chen M, Liu M et al. (2022) Semaphorin 5A suppresses ferroptosis through activation of PI3K-AKT-mTOR signaling in rheumatoid arthritis. Cell Death Dis 13:608. https://doi.org/10.1038/s41419-022-05065-4
  2. Chen K, Zeng H, Togizbayev G et al. (2023) New classification criteria for juvenile idiopathic arthritis. Int J Rheum Dis 26:1889–1892. https://doi.org/10.1111/1756-185X.14813
  3. Gras C, Eiz-Vesper B, Jaimes Y et al. (2014) Secreted semaphorin 5A activates immune effector cells and is a biomarker for rheumatoid arthritis. Arthritis Rheumatol 66:1461–1471. https://doi.org/10.1002/art.38425
  4. Petty RE, Southwood TR, Manners P et al. (2004) International league of associations for rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol 31:390–392. PMID: 14760812.
  5. Qin Y, Jin J, Zhang J et al. (2023) A fully human monoclonal antibody targeting Semaphorin 5A alleviates the progression of rheumatoid arthritis. Biomed Pharmacother 168:115666. https://doi.org/10.1016/j.biopha.2023.115666
  6. Sadanandam A, Rosenbaugh EG, Singh S et al. (2010) Semaphorin 5A promotes angiogenesis by increasing endothelial cell proliferation, migration, and decreasing apoptosis. Microvasc Res 79:1–9. https://doi.org/10.1016/j.mvr.2009.10.005
  7. Świdrowska-Jaros J, Smolewska E (2018) A fresh look at angiogenesis in juvenile idiopathic arthritis. Centr Eur J Immunol 43:325–330. https://doi.org/10.5114/ceji.2018.80052
  8. Xiao C, Lv C, Sun S et al. (2021) TSP1 is the essential domain of SEMA5A involved in pannus formation in rheumatoid arthritis. Rheumatology 60:5833–5842. https://doi.org/10.1093/rheumatology/keab133
  9. Zaripova LN, Midgley A, Christmas SE et al. (2021) Juvenile idiopathic arthritis: From aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J 19:135. https://doi.org/10.1186/s12969-021-00629-8
Language: English
Submitted on: Dec 7, 2024
Accepted on: Mar 13, 2025
Published on: May 28, 2025
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2025 Justyna Roszkiewicz, Krystyna Wyka, Elżbieta Smolewska, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.